Addition of lomustine for bevacizumab-refractory recurrent glioblastoma by Tonder, Michaela et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma
Tonder, Michaela; Eisele, Günter; Weiss, Tobias; Hofer, Silvia; Seystahl, Katharina; Valavanis,
Antonios; Stupp, Roger; Weller, Michael; Roth, Patrick
DOI: 10.3109/0284186X.2014.920960
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-97206
Akzeptierte Version
Originally published at:
Tonder, Michaela; Eisele, Günter; Weiss, Tobias; Hofer, Silvia; Seystahl, Katharina; Valavanis, Antonios;
Stupp, Roger; Weller, Michael; Roth, Patrick (2014). Addition of lomustine for bevacizumab-refractory
recurrent glioblastoma. Acta Oncologica, 53(10):1436-1440. DOI: 10.3109/0284186X.2014.920960
1 
 
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma 
 
 
Michaela Tonder, MD1, Günter Eisele, MD1, Tobias Weiss, MD1, Silvia Hofer, MD2, 
Katharina Seystahl, MD1, Antonios Valavanis, MD3, Roger Stupp, MD2, Michael Weller, 
MD1, Patrick Roth, MD1* 
 
 
Departments of 1Neurology and 2Oncology and 3Institute of Neuroradiology, University 
Hospital Zurich, CH-8091 Zurich, Switzerland 
 
 
*Correspondence: Dr. Patrick Roth, Department of Neurology and Brain Tumor Center 
Zurich, University Hospital Zurich, Frauenklinikstrasse 26, CH-8091 Zurich, Switzerland, 
Tel.: +41 44 255 5511, Fax: +41 44 255 4380, E-mail: patrick.roth@usz.ch 
 
Word count: 1290 
References: 22; Figures: 1 
 
 
Running title: Lomustine after failure of bevacizumab in glioblastoma patients 
Key words: glioblastoma, bevacizumab, lomustine, CCNU 
  
2 
 
To the editor: 
 
The current standard of care for patients with newly diagnosed glioblastoma consists of 
maximal safe surgical resection, followed by radiotherapy with concomitant and adjuvant 
chemotherapy with temozolomide for people younger than 65 years (1) and radiotherapy 
or chemotherapy with temozolomide alone for elderly patients depending on the 
methylation status of the O6-methylguanine DNA methyltransferase (MGMT) gene 
promoter (2, 3). Nevertheless, the tumor recurs in virtually all patients, and there is no 
agreed standard of care for progressive disease (4). Re-challenge with temozolomide and 
the administration of nitrosoureas are among the most frequently used options, 
particularly in patients who are still in overall good condition (5). In 2009, bevacizumab, a 
humanized monoclonal antibody against vascular endothelial growth factor (VEGF), was 
approved by the FDA but not in many other countries including those of the European 
Union for patients with recurrent or progressive glioblastoma (6, 7). The combination of 
bevacizumab with other cytotoxic agents such as irinotecan or temsirolimus has not 
provided signals of activity over those achieved with bevacizumab alone (7-11). 
Preliminary data suggest a putative benefit for the combination of bevacizumab and 
lomustine in patients with glioblastoma progressing after temozolomide-based 
chemoradiation (12). Upon further tumor progression on bevacizumab therapy, additional 
treatment options are urgently needed, but the activity of all agents tested so far was low. 
Whether bevacizumab should be stopped upon tumor progression or continued while 
adding another drug has also remained a matter of debate. While immediate 
discontinuation may result in progressive clinical deterioration due to withdrawal of the 
anti-edematous activity (13), the continued application may be associated with additional 
toxicity. Here we report our institutional experience with the addition of lomustine in 
patients with recurrent glioblastoma who progressed on bevacizumab monotherapy. 
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Patients and methods 
We retrospectively reviewed the tumor board proceedings from 2010-2013 for patients 
with recurrent glioblastoma treated with bevacizumab (10 mg/kg qow). Lomustine (CCNU, 
90-110 mg/m2 q 6 weeks) was added to the regimen upon further tumor progression while 
bevacizumab was continued. Magnetic resonance imaging (MRI) was performed in 8-12 
week intervals or upon clinical deterioration. Radiographic progression was defined by an 
increase of at least 25% of contrast enhancing tumor in T1 MRI scans or non-enhancing 
tumor in T2 MRI scans according to Response Assessment in Neuro-Oncology (RANO) 
criteria. Progression-free survival (PFS) was calculated according to the Kaplan-Meier 
method from the date of previous progression on bevacizumab monotherapy until the date 
of further progression on salvage bevacizumab plus lomustine therapy confirmed by MRI. 
Survival was calculated from the date of progression on treatment with bevacizumab 
monotherapy to the date of death. The total overall survival was calculated from the date 
of surgery to the date of death. Spearman rank correlation analysis was performed for 
time on bevacizumab monotherapy with survival after progression under bevacizumab 
monotherapy. No approval of the institutional ethics committee was needed for this 
retrospective anonymized analysis according to the local regulations. 
 
Results 
We identified 20 glioblastoma patients who had been treated with bevacizumab at tumor 
relapse and add-on lomustine escalation upon further progression. Table 1 summarizes 
essential patient characteristics including the applied treatment lines. The median age at 
diagnosis was 52.5 years (range 36 – 73 years) with a preponderance of males (14 
males, 6 women). Eighteen patients had received radiotherapy with concomitant and 
adjuvant temozolomide and two elderly patients had received radiotherapy or 
chemotherapy alone as first-line treatment depending on the MGMT promoter methylation 
status (4). In 15 patients, bevacizumab was introduced at first recurrence/progression, 
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and 5 patients received bevacizumab after re-exposure to a dose-intensified 
temozolomide regimen at initial tumor progression. Upon tumor progression on 
bevacizumab, all patients were continued on bevacizumab and treatment escalation was 
accomplished by the addition of lomustine at second (75%) or third (25%) tumor 
recurrence.  
The addition of lomustine was overall well tolerated. However, hematological toxicity was 
common. Twelve patients (60%) developed CTCAE grade 3-4 hematotoxicity. Of these, 
five patients (25%) had grade 3-4 leukopenia and neutropenia, four patients (20%) 
suffered from grade 3 thrombocytopenia and 3 (15%) patients developed grade 3-4 
lymphopenia. One patient received recombinant granulocyte-colony stimulating factor (G-
CSF, filgrastim) because of prolonged neutropenia resulting in a delay of 2 weeks of 
lomustine continuation and a lomustine dose reduction of 25%. 
The median PFS for patients on bevacizumab monotherapy at first or second tumor 
progression was 4.3 months. All patients received lomustine in combination with 
bevacizumab after progression on bevacizumab monotherapy. The median PFS (mPFS) 
after escalation of bevacizumab therapy with lomustine was 2.6 months. PFS at 6 months 
after the initiation of bevacizumab/lomustine was 0%. The median OS (mOS) after 
initiation of the bevacizumab/lomustine regimen was 5.1 months (Fig. 1A). There was a 
statistically significant correlation between the time on bevacizumab monotherapy with 
survival upon tumor progression (r = 0.5539 and p < 0.05 according to Spearman 
correlation analysis) (Fig. 1B). The mOS from initial diagnosis was 18.6 months. 
 
Discussion 
Controversy remains on optimal treatment of patients with recurrent glioblastoma. 
Although bevacizumab is commonly used, timing of administration and optimal patient 
management upon further progression remain undefined. Initial reports of high radiological 
response rates in patients with recurrent glioblastoma treated with bevacizumab led to 
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approval in the United Stated and in Switzerland, but not in the European Union (6, 7). 
Currently, there are no data to support the combination of bevacizumab with another 
agent in this indication (5). Furthermore, there is no consensus on how patients who 
experience further disease progression upon bevacizumab salvage therapy should be 
treated (9, 10). Lomustine has been used for a long time for the treatment of patients with 
recurrent glioblastoma and has also been frequently administered within clinical trials as 
the standard treatment arm (14, 15). Here we report that the addition of lomustine after 
progression on bevacizumab monotherapy as third- or fourth-line therapy fails to induce 
relevant disease stabilization, but is associated with hematological toxicity in 60% of these 
heavily pretreated patients. Our results are consistent with previous studies that had failed 
to show any benefit from therapy escalation with other drugs following disease 
progression under a bevacizumab-containing regimen (7, 9-11). 
In contrast to its questionable effect on overall survival, there are convincing data 
demonstrating an anti-edematous activity of bevacizumab (13). Although the decrease of 
the interstitial pressure should allow for a better distribution of cytotoxic agents into the 
tumor, the normalization of the blood-brain barrier function by bevacizumab may hamper 
the penetration of cytotoxic agents administered after tumor progression on bevacizumab 
therapy (16, 17). Thus, prior treatment with bevacizumab may preclude benefit from other 
agents administered afterwards. This mechanism has been shown in preclinical and 
clinical studies combining anti-angiogenic compounds with alkylating agents (18, 19). 
Other reports demonstrated a mOS of 5.9 months for bevacizumab continuation beyond 
initial progression on bevacizumab in patients with recurrent glioblastoma (20) which is 
similar to the results obtained with lomustine in our study. In patients with anaplastic 
gliomas, continuation of bevacizumab beyond progression did not result in promising 
survival data (21). A retrospective series analyzing the sequence of bevacizumab and 
lomustine revealed similar outcomes independent of which agent was used first. However, 
bevacizumab resulted in a longer PFS when it was administered first (22). Our data 
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suggest a positive correlation for the time on bevacizumab monotherapy with subsequent 
survival (Fig. 1B). A randomized phase II study compared bevacizumab or lomustine 
monotherapy with the combination of both agents in patients with first recurrence of 
glioblastoma. Here, a higher activity of the combined treatment approach yielding a PFS-6 
of 41% was observed compared to either treatment alone (12). Based on these findings, 
the EORTC 26101 trial has been amended and will be continued as a phase III study 
comparing lomustine monotherapy with the combination of bevacizumab and lomustine 
for glioblastoma patients with first tumor recurrence (NCT01290939). Only the results of 
this and similar trials will help to define the role of both compounds in the setting of 
recurrent glioblastoma. 
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Figure legend 
 
Figure 1. A. Progression-free and overall survival of 20 patients with second or third 
progression of glioblastoma treated with bevacizumab and lomustine upon progression on 
bevacizumab monotherapy (OS with 3 censored cases because of unknown time of death 
(n=2) or still alive (n=1) at the time of closure of the database). B. Correlation between 
time on bevacizumab monotherapy and survival following progression (p<0.05; Spearman 
correlation). 
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Table 1. Patient characteristics 
   Number 
of 
patients 
[n=20] 
Percentage 
[%] 
mPFS     
[months] 
 
 
Age (years) 
 
Median 
 
52.5 
    
 Range 36 - 73     
       
       
Sex Male  14 70   
       
 Female 
 
 6 30   
Chemotherapy       
1st line TMZ/RT→TMZ  18 90 7.7  
       
 TMZ 5/28  1 5 7.7  
       
 RT  1 5 2.7  
       
2nd line bevacizumab 
monotherapy 
 15 75 4.3                 
(combined 
analysis for 
2nd and 3rd 
line) 
 
       
 TMZ intensified  5 25 2  
       
3rd line bevacizumab 
monotherapy 
 5 25   
      Toxicity 
 bevacizumab + 
lomustine 
 15 75 2.6                 
(combined 
analysis for 
3rd and 4th 
line) 
• grade 3/4 leukopenia and 
neutropenia: 5 patients 
• grade 3 thrombocytopenia:         
4 patients 
• grade 3/4 lymphopenia: 
3 patients 
• treatment with recombinant G-
CSF because of prolonged 
neutropenia: 1 patient 
• non-hematologic: headache, 
fatigue and nausea: 3 patients 
 
      
4th line bevacizumab + 
lomustine 
 5 20  
 
Karnofsky performance score at 
initiation of bevacizumab and 
lomustine 
     
  100 0 0   
  90 6 30   
  80 8 40   
  70 3 15   
  60 2 10   
  50 1 5   
       
Steroid use at initiation of 
bevacizumab and lomustine 
     
  no 18 90   
  Yes 2 10   
       
       
MGMT status  methylated 2 10   
       
  unmethylated 5 25   
       
  not 
determined 
13 65   
Figure 1 
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